@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix pfh: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:11765; a Protein: . sub:_2 geneProductOf: pfh:AKT%20Family; a Protein: . sub:_3 occursIn: species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:TGFA) -> p(PFH:\"AKT Family\")" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "LS-174 was serum deprived and treated with PGE2 (0.1 micromolar) and TGF-alpha (100ng/ml), Western blot analysis showed that both PGE2 and TGF-alpha induced the levels of pAKT, and even combined treatment with PGE2 and TGFA resutled in a marked induction of PI3K activity."; prov:wasQuotedFrom pubmed:14500348 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:14500348; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:16.857+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }